616 related articles for article (PubMed ID: 28964430)
21. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
22. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
Jaime Caro J; Eddy DM; Kan H; Kaltz C; Patel B; Eldessouki R; Briggs AH;
Value Health; 2014 Mar; 17(2):174-82. PubMed ID: 24636375
[TBL] [Abstract][Full Text] [Related]
23. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report.
Malone DC; Ramsey SD; Patrick DL; Johnson FR; Mullins CD; Roberts MS; Willke RJ; Marshall DA
Value Health; 2020 Apr; 23(4):409-415. PubMed ID: 32327155
[TBL] [Abstract][Full Text] [Related]
24. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
[TBL] [Abstract][Full Text] [Related]
25. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
[TBL] [Abstract][Full Text] [Related]
26. Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG).
Yuan H; Ali MS; Brouwer ES; Girman CJ; Guo JJ; Lund JL; Patorno E; Slaughter JL; Wen X; Bennett D;
Clin Pharmacol Ther; 2018 Aug; 104(2):239-241. PubMed ID: 29733448
[TBL] [Abstract][Full Text] [Related]
27. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
Berger ML; Martin BC; Husereau D; Worley K; Allen JD; Yang W; Quon NC; Mullins CD; Kahler KH; Crown W
Value Health; 2014 Mar; 17(2):143-56. PubMed ID: 24636373
[TBL] [Abstract][Full Text] [Related]
28. Real-world evidence to support regulatory decision making: New or expanded medical product indications.
Franklin JM; Liaw KL; Iyasu S; Critchlow CW; Dreyer NA
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):685-693. PubMed ID: 33675248
[TBL] [Abstract][Full Text] [Related]
29. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance.
Jaksa A; Wu J; Jónsson P; Eichler HG; Vititoe S; Gatto NM
J Comp Eff Res; 2021 Jun; 10(9):711-731. PubMed ID: 33928789
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
[TBL] [Abstract][Full Text] [Related]
31. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making.
Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G
Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678
[TBL] [Abstract][Full Text] [Related]
32. Methodological challenges of comparative effectiveness research in pain: implications for investigators, clinicians, and policy makers.
Bellows BK; Biskupiak J
J Pain Palliat Care Pharmacother; 2011; 25(3):267-74. PubMed ID: 21882980
[TBL] [Abstract][Full Text] [Related]
33. A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms.
Beyrer J; Abedtash H; Hornbuckle K; Murray JF
J Comp Eff Res; 2022 May; 11(7):499-511. PubMed ID: 35296149
[No Abstract] [Full Text] [Related]
34. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
[TBL] [Abstract][Full Text] [Related]
35. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
[TBL] [Abstract][Full Text] [Related]
36. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
37. Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs.
Thieffry S; Klein P; Baulac M; Plumb J; Pelgrims B; Steeves S; Borghs S
Epilepsia; 2020 Apr; 61(4):595-609. PubMed ID: 32201951
[TBL] [Abstract][Full Text] [Related]
38. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.
Matza LS; Patrick DL; Riley AW; Alexander JJ; Rajmil L; Pleil AM; Bullinger M
Value Health; 2013 Jun; 16(4):461-79. PubMed ID: 23796280
[TBL] [Abstract][Full Text] [Related]
39. PEER-REVIEWED JOURNAL EDITORS' VIEWS ON REAL-WORLD EVIDENCE.
Oehrlein EM; Graff JS; Perfetto EM; Mullins CD; Dubois RW; Anyanwu C; Onukwugha E
Int J Technol Assess Health Care; 2018 Jan; 34(1):111-119. PubMed ID: 29415784
[TBL] [Abstract][Full Text] [Related]
40. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
Crown W; Buyukkaramikli N; Sir MY; Thokala P; Morton A; Marshall DA; Tosh JC; Ijzerman MJ; Padula WV; Pasupathy KS
Value Health; 2018 Sep; 21(9):1019-1028. PubMed ID: 30224103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
